Overview

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Fred Hutchinson Cancer Research Center
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine